ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Inipharm raises funds to advance liver drug

by Michael McCoy
November 14, 2020 | APPEARED IN VOLUME 98, ISSUE 44

 

Inipharm has raised $35 million in series A financing from 5AM Ventures, Wu Capital, and existing investors. Founded in 2018, Inipharm is developing small-molecule drugs that modulate HSD17B13, a gene associated with liver diseases including nonalcoholic steatohepatitis (NASH), which is the target of numerous drug development efforts. Regeneron and Alnylam, for example, are testing RNA interference to combat NASH.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment